Methods for detecting nucleic acids indicative of cancer

Information

  • Patent Grant
  • 6964846
  • Patent Number
    6,964,846
  • Date Filed
    Friday, April 7, 2000
    25 years ago
  • Date Issued
    Tuesday, November 15, 2005
    19 years ago
Abstract
The invention provides methods for screening tissue or body fluid samples for nucleic acid indicia of cancer or precancer.
Description
FIELD OF THE INVENTION

This invention relates to methods for the early detection of cancer in patients by screening for large DNA fragments. Methods of the invention are especially useful in the detection of colon cancer.


BACKGROUND OF THE INVENTION

Alterations in genomic integrity often are associated with disease or with the propensity for disease. For example, many cancers are thought to arise through a series of mutations in genomic DNA, resulting in genomic instability in the form of uncontrolled cellular growth. In normal cells, damage to genomic DNA typically leads to expression of tumor suppressors, such as the cell-cycle regulator, p53. For example, damage to cellular DNA results in increased expression of p53 which arrests the cell cycle to allow repair of the damage. If the damaged DNA cannot be repaired, the cell undergoes apoptosis, thus preventing the accumulation of additional mutations in daughter cells. If however, there is a mutation in the p53 gene itself (or in another cell cycle regulator), damaged cells will proceed through the cell cycle, giving rise to progeny in which additional DNA mutations will go unchecked. It is the accumulation of these mutations that is the hallmark of many cancers.


The process of apoptosis is important not only in the regulation of cellular metabolism, but also in inhibiting oncogenesis. As cells undergo apoptosis, the nucleus becomes small and fragmented. Nuclear DNA is digested into spindle fragments that are generally no larger than about 200 base pairs. As the process continues, usually through multiple pathways, the cell membrane breaks down, and cellular contents are metabolized. As a result, cells that have the potential to enter the multi-step pathway leading to cancer are eliminated.


Many cancers are curable if detected early in their development. For example, colorectal cancers typically originate in the colonic epithelium, and are not extensively vascularized (and therefore not invasive) during early stages of development. The transition to a highly-vascularized, invasive and ultimately metastatic cancer commonly takes ten years or longer. If the presence of cancer is detected prior to extensive vascularization, surgical removal typically is an effective cure. However, colorectal cancer is often detected only upon manifestation of clinical symptoms, such as pain and black tarry stool. Generally, such symptoms are present only when the disease is well established, and often after metastasis has occurred. Early detection of colorectal cancer therefore is important in order to significantly reduce its morbidity.


Invasive diagnostic methods, such as endoscopic examination, allow direct visual identification, removal, and biopsy of potentially-cancerous tissue. Endoscopy is expensive, uncomfortable, inherently risky, and not a practical tool for early diagnosis.


Established non-invasive screening methods involve assaying stool samples for the presence of fecal occult blood or for elevated levels of carcinoembryonic antigen, both of which are suggestive of the presence of colorectal cancer. Additionally, recent developments in molecular biology provide methods of great potential for detecting the presence of a range of DNA mutations indicative of colorectal cancer. The presence of such mutations can be detected in DNA found in stool samples during various stages of colorectal cancer. However, stool comprises cells and cellular debris from the patient, from microorganisms, and from food, resulting in a heterogeneous population of cells. This makes detection of small, specific subpopulations difficult to detect reliably.


There is a need in the art for additional non-invasive methods for early diagnosis of cancer that will detect characteristics indicative of the presence of cancer.


SUMMARY OF THE INVENTION

The present invention provides methods for identifying indicia of cancer in tissue or body fluid samples by identifying non-apoptotic DNA in those samples. The invention also provides methods for identifying indicia of cancer or precancer in samples containing exfoliated epithelial cells. It has now been recognized that DNA obtained from exfoliated normal (non-cancerous) cells is different than DNA obtained from exfoliated cancer or precancer cells. Normal exfoliated cells typically have undergone apoptosis, and thus produce cells or cellular debris (depending upon the stage of apoptosis) comprising DNA that has been substantially degraded. Exfoliated cancer or precancer cells typically have not undergone apoptosis, and such cells or their debris, while producing some very small fragments as a result of degradation in the sample, typically also contain a higher proportion of large DNA fragments (compared to those observed in cells or debris from exfoliated normal cells). The difference in DNA integrity between normal and abnormal cells is a marker for the presence of cancer or precancer in a sample comprising exfoliated cells.


Stool is a good sample for exemplification of methods of the invention. The colonic epithelium undergoes a continual process of exfoliation. Normal epithelial cells undergo apoptosis, and are sloughed into the lumen of the colon, and onto forming stool. Cells from polyps and tumors are also sloughed onto forming stool. However, cells from polyps or tumors are, by definition, not apoptotic. Methods of the invention take advantage of the different characteristics between apoptotic and non- apoptotic cells in order to screen patient samples for indicia of cancer or precancer.


As noted above, non-cancerous (normal) cells undergo apoptosis at regular intervals, or in response to irreparable cell damage. As a result of apoptosis, DNA from normal cells is cleaved into small fragments having about 200 or fewer base pairs, and typically 180 base pairs or less. In contrast, DNA obtained from cancer or precancer cells is much larger than the typical apoptotic fragments. Thus, the presence of large DNA fragments in a sample (e.g., of sloughed colonic epithelium) indicates that there are or were cells in the sample (or the specimen from which it was obtained) that have avoided apoptosis, and its coincidental degradation of DNA. The presence of large DNA fragments represents a positive screen for cancer or precancer.


Accordingly, methods of the invention comprise detecting the presence in a biological sample of species-specific nucleic acids indicative of cancer or precaner. Samples comprising such nucleic acids are identified as having indicia of cancer or precancer. In preferred methods, patients presenting samples having a high proportion of non-apoptotic nucleic acids as determined by methods of the Invention are further evaluated for the presence of a tumor, adenoma, or other cancerous or precancerous lesion.


In general, methods of the invention comprise detecting in a biological sample one or more DNA fragment(s) of a length that would not be substantially present in noncancerous cells or cellular debris. In a preferred embodiment, such fragments are larger than a typical apoptotic spindle fragment, or larger than about 170 base pairs. However, also in a preferred embodiment, methods of the invention comprise detecting DNA fragments that are greater than about 200 base pairs, and preferably greater than about 500 base pairs. There is no upper limit on these fragments, as all that is necessary is that the fragment be larger than an apoptotic fragment. Typically, however, fragments indicative of cancer or precancer cells are between about 200 and about 3500 base pairs, and ideally between about 500 and about 2500 base pairs.


Accordingly, in a preferred embodiment, methods of the invention comprise detecting in a tissue or body fluid sample the presence of nucleic acid fragments having greater than about 500 base pairs or having a molecular weight corresponding to greater than about 500 base pairs. In other preferred embodiments, methods of the invention comprise detecting nucleic acid fragments having between about 200 and about 1000 base pairs, preferably between about 200 and about 600 base pairs, and most preferably about 500 base pairs.


Also in a preferred embodiment, methods of the invention comprise determining a ratio of large fragments (200-3500 bp) to small fragments (less than 200 bp), and determining whether the ratio exceeds an empirically-derived threshold. The threshold is determined empirically by analyzing ratios of large-to-small fragments, and correlating those ratios with the disease state of a selected population of normal and cancer patients. In preferred embodiments, amounts of large and small fragments are determined by polymerase chain reaction amplification of sample DNA using primers selected to amplify long and short fragments. Alternatively, amounts of large and small fragments are determined using the same primer.


Preferred methods of the invention comprise amplifying nucleic acids in a representative stool sample using human-specific primers, and detecting amplicons 5 having greater than about 200, and preferably about 500 or more base pairs. In a highly-preferred embodiment, amplification is accomplished by polymerase chain reaction (PCR) using forward and reverse primers directed against human-specific nucleic acid fragments, and spaced apart to provide a lower limit on the resulting amplicons. Also in a highly-preferred embodiment, primers for PCR are directed against human oncogene or tumor suppressor sequences. Preferred target nucleic acids for PCR primers include p53, Kras, apc, dcc, and other genes known or suspected to be associated with cancer, and especially colorectal cancer. Methods for conducting PCR are provided in U.S. Pat. No. 4,683,202, incorporated by reference herein. The presence of amplicon greater than about 200 base pairs in length is indicative of template nucleic acid in the sample of that length (or longer). According to methods of the invention such long sequences represent a positive screen, and are indicative of cancer or precancer.


Preferred biological samples include stool, pus and urine. Method of the inventions are especially useful for the detection of large DNA fragments in samples comprising exfoliate. Tissue (e.g., colon, lungs, bladder) in which cells, especially epithelial cells, are exfoliated are most preferred for screening methods of the invention. In such tissues, continuing cellular renewal requires that cells are regularly sloughed after having undergone apoptosis. Samples of the exfoliate (tissue or body fluid containing the exfoliated cells) predominantly comprise apoptotic DNA.


Preferred methods of the invention for use on a stool sample comprise obtaining a representative stool sample. An especially-preferred method for preparing a stool sample is disclosed in U.S. Pat. No. 5,741,650, and in co-owned, co-pending U.S. patent application Ser. No. 09/059,713 , each of which is incorporated by reference herein.


In a preferred embodiment, methods of the invention comprise homogenizing a representative stool sample in a solvent in order to form a homogenized sample mixture having a solvent volume to stool mass ratio of at least 5 to 1. An especially-preferred ratio of solvent volume to stool mass is about 20:1. A preferred solvent for preparing stool samples according to the invention is a physiologically-compatible buffer comprising a detergent and a proteinase and optionally a DNase inhibitor, such as a buffer comprising Tris-EDTA-NaCl. A preferred buffer is 50 mM Tris, 150 mM EDTA and 10 mM NaCI at pH 9.0. Another preferred solvent is guanidine isothiocyanate (GITC). Providing an optimal solvent volume to stool mass ratio increases the yield of nucleic acid generally from the sample. Further details regarding sample preparation are disclosed in co-owned, co-pending U.S. patent application Ser. No. 09/198,083 incorporated herein by reference.


Preferred methods of the invention further comprise enriching sample for human DNA. Preferred enrichment methods for use in the invention include enriching a desired human target sequence using an affinity column, sequence-specific capture, or through the use of preferred buffers that bias isolation of human DNA. A preferred enrichment method is based upon the capture of unique human nucleic acids using, for example, an affinity column. Details of such methods are provided below.


In a preferred embodiment, methods further comprise the step of extracting DNA from the homogenized sample mixture using sequence-specific nucleic acid probes. Particularly preferred are probes hybridizing to human DNA. The probes are preferably labeled. Preferred labels include radioactive labels, fluorescent labels, molecular weight labels and enzymatic labels. Other labels are well known in the art.


In a preferred embodiment gel electrophoresis, affinity chromatography, or mass spectrometry are used to detect large DNA fragments (fragments comprising greater than about 200 base pairs). The presence of large DNA fragments in the sample is indicative of colorectal cancer.


In a preferred embodiment capture probes comprise DNA, RNA or PNA, and are detectably labeled using methods known in the art. In one embodiment probes are labeled with radioactive isotopes such as 32p, 33p, 35S, 125I, or any other detectable isotope useful for labeling a hybridization probe. In an another embodiment, probes are labeled with fluorescent molecules. Numerous fluorescent labels are known in the art, and any detectable fluorescent probe label is useful for practice of the invention. Alternatively, probes are attached to moieties which increase their molecular weight. For example a probe may be directly attached to a glycoprotein, or a glass bead, or any compound which has a detectable effect on the molecular weight of the probe. In a further embodiment, probes are labeled with a compound that is detectable due to specific interactions with an additional compound. For example, biotinylated probes are detectable via interaction with streptavidin. The streptavidin moiety is attached to a detectable label such as a bead, a fluorescent tag, or an enzyme. In another example, the probes are labeled with a hapten or other antigen which is specifically recognized by an antibody. The antibody is made detectable using methods known in the art including radioactive isotopes, fluorescent tags, and enzyme reactions. In a further example the probes are directly attached to an enzyme which is detectable via a specific enzyme catalyzed reaction generating a detectable product.


Finally, methods of the invention allow one to approximate the position in the colon of a colorectal lesion based upon the relative amount of DNA fragments in a stool sample that are greater than 200 base pairs in length. This aspect of the invention relies on the fact that the lytic properties of stool are greater in the proximal colon than they are in the distal colon. In the proximal colon, stool is typically in liquid form. Therefore, the cell lysis and DNA degrading enzymes in the colon have greater access to exfoliated cells in the liquid mixture of the proximal colon as compared to their access to exfoliated cells sloughed onto formed or forming stool that is typical in the distal colon. As a consequence of the differences between the environments of the proximal and distal colon, the present invention provides that typical DNA fragments from cells exfoliated into the proximal colon are smaller than DNA fragments from cells exfoliated into the distal colon. FIG. 1 provides an example of the progression of DNA sizes expected for cancer or precancer cells exfoliated into different regions of the colon. The size of DNA fragments from noncancerous or precancerous cells is the same throughout the colon due to the fact that the DNA from those cells is degraded primarily through apoptosis. Thus, cell lysis and DNA degradation play only minor roles in determining the size of DNA fragments from most exfoliated normal cells throughout the colon. It is noted, however, that normal cells that are, for example, mechanically sheared from the colon undergo the same lytic and degradation cycle as the typical cancer or precancer cell. However, the contribution of such non-apoptotic normal cells to the overall level of DNA in the stool sample is small, and is controlled for by establishing standards as taught below.


Further aspects and advantages of the invention are contained in the following detailed description thereof.





DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a schematic representation of the colon, and the representative (typical) DNA fragment length for DNA obtained from a cancer or precancer exfoliated cell over the representative (typical) apoptotic (normal) DNA fragment length for various regions of the colon.



FIG. 2 is a gel photograph showing results of amplification of Kras (exon 1) DNA isolated from stool using forward and reverse primers spaced about 200 bp apart. The band Intensity relates to the amount of 200 bp product or greater in the sample. Lanes 1-4 are results from patients with cancer or adenoma, lane 5 is a positive control, lanes 6-10 are from patients who did not have cancer or adenoma, lanes 11-12 are negative controls, and lanes 13-18 are standards at the approximate molecular weight indicated in the figure.



FIG. 3 is a gel photograph showing results of amplification of apc (exon 15) DNA isolated from stool using forward and reverse primers spaced about 200 bp apart. The band intensity relates to the amount of 200 bp product or greater in the sample. Lanes 1-4 are results from patients with cancer or adenoma, lane 5 is a positive control, lanes 6-10 are from patients who did not have cancer or adenoma, lanes 11-12 are negative controls, and lanes 13-18 are standards at the approximate molecular weight indicated in the figure.



FIG. 4 is a gel photograph showing results of amplification of apc (exon 15) DNA isolated from stool using forward and reverse primers spaced about 200 bp apart. The band intensity relates to the amount of 200 bp product or greater in the sample. Lanes 1-4 are results from patients with cancer or adenoma, lane 5 is a positive control, lanes 6-10 are from patients who did not have cancer or adenoma, lanes 11-12 are negative controls, and lanes 13-18 are standards at the approximate molecular weight indicated in the figure.



FIG. 5 is a gel photograph showing results of amplification of apc (exon 15) DNA isolated from stool using forward and reverse primers spaced about 200 bp apart. The band intensity relates to the amount of 200 bp product or greater in the sample. Lanes 1-4 are results from patients with cancer or adenoma, lane 5 is a positive control, lanes 6-10 are from patients who did not have cancer or adenoma, lanes 11-12 are negative controls, and lanes 13-18 are standards at the approximate molecular weight indicated in the figure.



FIG. 6 is a gel photograph showing results of amplification of p53 (exon 5) DNA isolated from stool using forward and reverse primers spaced about 200 bp apart. The band intensity relates to the amount of 200 bp product or greater in the sample. Lanes 1-4 are results from patients with cancer or adenoma, lane 5 is a positive control, lanes 6-10 are from patients who did not have cancer or adenoma, lanes 11-12 are negative controls, and lanes 13-18 are standards at the approximate molecular weight indicated in the figure.



FIG. 7 is a gel photograph showing results of amplification of p53 (exon 7) 25 DNA isolated from stool using forward and reverse primers spaced about 200 bp apart. The band intensity relates to the amount of 200 bp product or greater in the sample. Lanes 1-4 are results from patients with cancer or adenoma, lane 5 is a positive control, lanes 6-10 are from patients who did not have cancer or adenoma, lanes 11-12 are negative controls, and lanes 13-18 are standards at the approximate molecular weight indicated in the figure.



FIG. 8 is a gel photograph showing results of amplification of p53 (exon 8) DNA isolated from stool using forward and reverse primers spaced about 200 bp apart. The band intensity relates to the amount of 200 bp product or greater in the sample. Lanes 1-4 are results from patients with cancer or adenoma, lane 5 is a positive control, lanes 6-10 are from patients who did not have cancer or adenoma, lanes 11-12 are negative controls, and lanes 13-18 are standards at the approximate molecular weight indicated in the figure.



FIG. 9 is a gel photograph of results of amplification of DNA from stool samples using forward and reverse primers spaced approximately 1.8 Kb apart. The band intensity shows the amount of 1.8 Kb or greater product. Lanes 1, 8, and 9 are negative controls, lanes 2, 3 , and 5 are results from patients with cancer or adenoma, lanes 4, 6 , and 7 are results from patients who did not have cancer or adenoma, and lanes 10-14 are molecular weight standards.



FIG. 10 is a gel photograph of results of amplification of DNA from stool samples using forward and reverse primers spaced approximately 1.8 Kb apart. The band intensity shows the amount of 1.8 Kb or greater product. Lanes 1, 8 , and 9 are negative controls, lanes 2, 3, and 5 are results from patients with cancer or adenoma, lanes 4, 6, and 7 are results from patients who did not have cancer or adenoma, and lanes 10-14 are molecular weight standards.



FIG. 11 is a gel photograph of results of amplification of DNA from stool samples using forward and reverse primers spaced approximately 1.8 Kb apart. The band Intensity shows the amount of 1.8 Kb or greater product. Lanes 1, 8, and 9 are negative controls, lanes 2, 3, and 5 are results from patients with cancer or adenoma, lanes 4, 6, and 7 are results from patients who did not have cancer or adenoma, and lanes 10-14 are molecular weight standards.





DETAILED DESCRIPTION OF THE INVENTION

Methods of the invention are based upon the observation that samples comprising cells from patients with cancer or precancer contain a greater amount of high molecular weight (long sequence) DNA fragments as compared to corresponding samples obtained from individuals that are free of cancer/precancer. Accordingly, methods of the invention provide accurate screening and diagnostic procedures for cancer or precancer.


Methods of the invention are useful to detect nucleic acid indicia of cancer or precancer in any tissue or body fluid sample. For example, sputum samples are used to detect the presence of high molecular weight (long sequence) DNA as a marker for cancer. The majority of cells exfoliated into sputum have undergone apoptosis and subsequent further enzymatic degradation. The predominant DNA from those cells is small, apoptotic DNA. Cancer cells produced by, for example, the lungs, the nasal passages, or the trachea will also be sloughed into sputum. However, the DNA from those cells, while being exposed to enzymatic processes, has not been affected by apoptosis. Accordingly, fragments from cancer or precancer cells found in sputum are larger than fragments expected to be produced by normal cells.


Similarly, cells sloughed by cancerous or precancerous lesions in the bladder or kidney produce non-apoptotic DNA in urine, cancerous or precancerous lesions in the lymph nodes result in non-apoptotic DNA fragments in lymph, and cancerous or precancerous cells in the breast slough non-apoptotic DNA-containing cells that can be harvested via aspiration. Accordingly, methods of the invention are useful in any tissue or body fluid. However, for purposes of exemplification of the methods described herein, stool sample were used to predict the presence of colorectal cancer or precancer. Stool Is an excellent specimen for analysis due to the characteristic exfoliation of colonic epithelia as described above.


Methods of the invention are practiced by detecting the presence of DNA fragments having a sequence length that would not be expected to be present in significant amounts in a sample obtained from a healthy individual (i.e., an individual who does not have cancer or precancer). A threshold amount of large fragments is an amount that exceeds a predetermined level expected or determined for non-cancerous/non-precancerous cells. The predetermined level or standard can be determined by detecting the amount of a particular size of DNA fragment (preferably apoptotic fragments characteristic of normal cells) in a population or subpopulation of normal patients. Standards can be determined empirically, and, once determined, can be used as the basis for further screening.


The size of fragments to be used is chosen based upon the convenience of the individual performing the screen. Factors affecting the size of fragments used in screening or diagnostic methods of the invention Include the availability and costs of probes and primers, the desired target of amplification, the type of cancer being screened, and the patient sample on which screening takes place. The invention takes advantage of the recognition that large fragments exist in greater abundance in abnormal samples than in normal samples. Accordingly, the precise size of fragments used in methods of the invention does not matter. For any given size of fragments to be analyzed, a cutoff must be determined to distinguish between normal and abnormal samples. Preferably, the cutoff is determined empirically based upon known normal and abnormal sample, and then is used in future screenings.


The following examples provide further details of methods according to the invention. For purposes of exemplification, the following examples provide details of the use of the method if the present invention in colon cancer detection. Accordingly, while exemplified in the following manner, the invention is not so limited and the skilled artisan will appreciate its wide range of application upon consideration thereof.


Exemplary Method for the Detection of Colon Cancer


For the analysis of stool samples, preferred methods of the invention comprise obtaining at least a cross-section or circumfrential portion of a voided stool as taught in U.S. Pat. No. 5,741,650, and co-pending, co-owned U.S. patent application Ser. No. 09/059,718, both of which are incorporated by reference herein. While a cross-sectional or circumfrential portion of stool is desirable, methods provided herein are conducted on random samples obtained from voided stool, which include smears or scrapings. Once obtained, the stool specimen Is homogenized. A preferable buffer for homogenization is one that contains at least 16 mM ethylenediaminetetraacetic acid (EDTA). However, as taught in co-pending, co-owned U.S. patent application Ser. No. 60/1122,177, incorporated by reference herein, it has been discovered that the use of at least 150 mM EDTA greatly improves the yield of nucleic acid from stool. Thus, a preferred buffer for stool homogenization comprises phosphate buffered saline, 20-100 mM NaCl or KCl, at least 150 mM EDTA, and optionally a detergent (such as SDS) and a proteinase (e.g., proteinase K).


After homogenization, nucleic acid is preferably isolated from the stool sample. Isolation or extraction of nucleic acid is not required in all methods of the invention, as certain detection techniques can be adequately performed in homogenized stool without isolation of nucleic acids. In a preferred embodiment, however, homogenized stool is spun to create a supernatant containing nucleic acids, proteins, lipids, and other cellular debris. The supernatant is treated with a detergent and proteinase to degrade protein, and the nucleic acid is phenol-chloroform extracted. The extracted nucleic acids are then precipitated with alcohol. Other techniques can be used to isolate nucleic acid from the sample. Such techniques include hybrid capture, and amplification directly from the homogenized stool. Nucleic acids can be purified and/or isolated to the extent required by the screening assay to be employed. Total DNA is isolated using techniques known in the art.


Once DNA is isolated, the sample preferably is enriched for human nucleic acids using sequence specific capture probes. Pelletized DNA is resuspended in TE buffer. Guanidine isothiocyanatate (GITC) is then added. An excess of capture probes that target human DNA are added to the sample. The sample is heated to denature the DNA and then cooled. Finally, probe and target DNA are allowed to hybridize. Steptavidin -coated magnetized beads are suspended in water and added to the mixture. After briefly mixing, the mixture is maintained at room temperature for approximately 30 minutes. Once the affinity binding is completed, a magnetic filed is applied to the sample to draw the magnetized isolation beads (both with and without hybridized complex). The beads are then washed four (4) times in 1M GITCI0.1% Igepal (Sigma, St. Louis, Mo.) solution for 15 minutes, followed by two (2) washes with warm buffer (TE with 1M NaCl) for 15 minutes in order to isolate complexed streptavidin. Finally, distilled water is added to the beads and heated to elude the DNA. Gel electrophoresis can then be performed on the human DNA that has been captured.


III. Determination of Fragment Length


The size of human DNA fragments obtained above can be determined by numerous means. For example, human DNA can be separated using gel electrophoresis. A 5% acrylamide gel is prepared using techniques known in the art. See Ausubel et. al., Short Protocols in Molecular Biology, John Wiley & Sones, 1195, pgs. 2-23-2-24, incorporated by reference herein. The size of human DNA fragments is then determined by comparison to known standards. Fragments greater than about 200 bp provide a positive screen. While a diagnosis can be made on the basis of the screen alone, patients presenting a positive screen are preferably advised to seek follow-up testing to render a confirmed diagnosis.


A preferred means for determining human DNA fragment length is by using PCR. Methods for implementing PCR are well-known. In the present invention, human DNA fragments are amplified using human-specific primers. Amplicon of greater than about 200 bp produced by PCR represents a positive screen. Other amplification reactions and modifications of PCR, such as ligase chain reaction, reverse-phase PCR, Q-PCR, and others may be used to produce detectable levels of amplicon. Amplicon may be detected by coupling to a reporter (e.g. flouresence, radioisotopes, and the like), by sequencing, by gel electrophoresis, by mass spectrometry, or by any other means known in the art, as long as the length, weight, or other characteristic of the amplicons identifies them by size.


EXAMPLES

Experiments were conducted to determine whether characteristics of amplifiable DNA in stool were predictive of cancer or precancer in patients from whom stools samples were obtained. In the first experiment, the amount of amplifiable DNA was measured in each of several stool samples using PCR amplification to detect DNA fragments in the sample of at least 200 base pairs in length. The second experiment determined the amount of long (greater than 200 base pair) fragments in the same samples, and then to determine ratios of long product to short product.


I. The Use of Amplifiable DNA as a Marker for Cancer or Precancer


Stool samples were collected from 9 patients who presented with symptoms or a medical history that indicated that a colonoscopy should be performed. Each stool sample was frozen. Immediately after providing a stool sample, each patient was given a colonoscopy in order to determine the patient's disease status. Based upon the colonoscopy results, and subsequent histological analysis of biopsy samples taken during colonsocopy, individuals were placed into one of two groups: normal or abnormal. The abnormal group consisted of patients with cancer or with an adenoma of at least 1 cm in diameter. Based upon these results, 4 of the 9 patients were placed into the abnormal group.


The samples were screened by hybrid capturing human DNA, and determining the amount of amplifiable DNA having at least 200 base pairs. Each frozen stool specimen, weighing from 7-33 grams, was though and homogenized in 500 mM Tris, 16 mM EDTA, and 10 mM NaCl, pH 9.0 at a volume: to mass ratio of 3:1. Samples were then rehomogenized in the same buffer to a final volume-to-mass ratio of 20:1, and spun in glass macro beads at 2356×g. The supernatant was collected and treated with SDS and proteinase k. The DNA was then phenol-chloroform extracted and precipitated with alcohol. The precipitate was suspended In 10 mM Tris and 1 mM EDTA.(1×TE), pH 7.4. Finally, the DNA was treated with Rnase.


Human DNA was isolated from the precipitate by sequence-specific hybrid capture. Biotynilated probes against portions of the p53, K-ras, and apc genes were used. The K-ras probe was 5′GTGGAGTATTTGATAGTGTATTAACCTTATGTGTGAC 3′ (SEQ ID NO: 1). There were two apc probes: apc-1309 was 5′TTCCAGCAGTGTCACAGCACCCTAGAACCAAATCCAG 3′ (SEQ ID NO: 2), and apc-1378 was 5′CAGATAGCCCTGGACAAACAATGCCACGAAGCAGAAG 3′ (SEQ ID NO: 3). There were four probes against p53, the first (hybridizing to a portion of exon 5) was 5′TACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGG3′ (SEQ ID NO:4), the second (hybridizing to a portion of exon 7) was 5′ATTTCTTCCATACTACTACCCATCGACCTCTCATC3′ (SEQ ID NO: 5), the third, also hybridizing to a portion of exon 7 was 5′ATGAGGCCAGTGCGCCTTGGGGAGACCTGTGGCAAGC3′ (SEQ ID NO: 6); and finally, a probe against exon 8 had the sequence 5′GAAAGGACAAGGGTGGTTGGGAGTAGATGGAGCCTGG3′ (SEQ ID NO: 7). A 10 ul aliquot of each probe (20 pmol/capture) was added to a suspension containing 300 ul DNA in the presence of 310 ul 6M GITC buffer for 2 hours at room temperature. Hybrid complexes were isolated using streptavidin-coated beads (Dynal). After washing, probe-bead complexes were suspended at 25° C. for 1 hour in 0.1×TE buffer, pH7.4. The suspension was then heated for 4 minutes at 85° C., and the beads were removed.


Captured DNA was then amplified using PCR, essentially as described in U.S. Pat. No. 4,683,202, incorporated by reference herein. Each sample was amplified using forward and reverse primers through 7 loci (Kras, exon 1, APC exon 15 (3 separate loci), p53, exon 5, p53, exon 7, and p53, exon 8) in duplicate (for a total of 14 amplifications for each locus). Seven separate PCRs (33 cycles each) were run in duplicate using primers directed to detect fragments in the sample having 200 base pairs or more. Amplified DNA was placed on a 4% Nusieve (FMC Biochemical) gel (3% Nusieve, 1% agarose), and stained with ethidium bromide (0.5 ug/ml). The resulting amplified DNA was graded based upon the relative intensity of the stained gels. The results are shown in FIGS. 2-8. Each Figure represents the results for all 9 patients (including standards) for the seven different loci that were amplified. As shown in the Figures, each sample from a patient with cancer or adenoma was detected as a band having significantly greater intensity than the bands associated with samples from patients who did not have cancer or precancer. All four cancer/adenoma patients identified using colonoscopy were correctly identified by determining the amount of amplifiable DNA 200 base pairs or greater in length. As shown in FIGS. 2-8, the results were the same regardless of which locus was amplified. Accordingly, the amount of 200 bp or greater DNA in a sample was predictive of patient disease status.


EXAMPLE 2

An experiment was conducted that was essentially identical to the one described above in Example 1, but forward and reverse primers were placed such that fragments of about 1.8 Kb and above were amplified.


DNA was prepared as described above. Forward and reverse primers were spaced so as to hybridize approximately 1.8 Kb apart on three different loci (Kras, exon 1, APC, exon 15, and p53 exon 5). Thirty-three rounds of amplification were performed, and the resulting DNA was placed on a 5% acrylamide gel. The results are shown in FIGS. 9-11. As shown in the Figures (which show results from three separate experiments to amplify and detect “long” product), samples from individuals having cancer or precancer produced large amounts of high-molecular weight (in this case 1.8 Kb and above) DNA; whereas samples from patients who did not have cancer or precancer produced no DNA In the range of about 1.8 Kb and higher. Thus, the presence of high-molecular weight DNA was indicative of the disease status of the patient.


The invention has been described in terms of its preferred embodiments. Alternative embodiments are apparent to the skilled artisan upon examination of the specification and claims.

Claims
  • 1. A method for screening a patient for a colorectal cancer or a colorectal precancer, the method comprising the steps of: detecting in a patient stool sample comprising exfoliated cells or cellular debris a first amount of a long nucleic acid of a length greater than 200 base pairs in length; wherein said long nucleic acid is present in both normal and cancerous or precancerous cells; comparing the first amount of long nucleic acid in said patient stool sample to a second amount of said long nucleic acid present in a stool sample from patient free of colorectal cancer or precancer; determining whether said first amount of long nucleic acid exceeds the second amount of long nucleic acid in said sample from a patient free of colorectal cancer or precancer; and; identifying a positive screen for an indicator of a colorectal cancer or precancer if said amount of long nucleic acid in said patient stool sample does exceed said second amount of long nucleic acid in said sample from a patient free of colorectal cancer or precancer.
  • 2. The method for screening a patient for a colorectal cancer or a colorectal precancer, the method comprising the steps of: determining in patient stool sample comprising exfoliated cells or cellular debris a first amount of long nucleic acid of a length greater then 200 base pairs; determining in said stool sample a second amount of nucleic acid of a length less than said long nucleic acid; determining a ratio between said first amount and said amount; and identifying a positive screen for an indicator of a colorectal cancer or precancer if said ratio exceeds a threshold ratio for patient who do not have a colorectal cancer or a precancer.
  • 3. The method of claim 1 or claim 2, wherein said detecting or determining comprises conducting an amplification reaction designed to amplify only nucleic acids fragments that are greater than 200 base pair in length.
  • 4. The method of claim 1 or claim 2, further comprising the step of enriching said sample for human DNA.
  • 5. The method of claim 1 or claim 2, further comprising the step of isolating human DNA from said sample.
Parent Case Info

This application claims benefit of U.S. provisional patent application, Ser. No. 60/128,629 field Apr. 9, 1999, the disclosure of which is incorporated by reference herein.

US Referenced Citations (128)
Number Name Date Kind
3413464 Kamentsky Nov 1968 A
4101279 Aslam Jul 1978 A
4309782 Paulin Jan 1982 A
4333734 Fleisher Jun 1982 A
4358535 Falkow et al. Nov 1982 A
4445235 Slover et al. May 1984 A
4535058 Weinberg et al. Aug 1985 A
4578358 Oksman et al. Mar 1986 A
4683195 Mullis et al. Jul 1987 A
4683202 Mullis Jul 1987 A
4705050 Markham Nov 1987 A
4735905 Parker Apr 1988 A
4786718 Weinberg et al. Nov 1988 A
4857300 Maksem Aug 1989 A
4871838 Bos et al. Oct 1989 A
4935342 Seligson et al. Jun 1990 A
4981783 Augenlicht Jan 1991 A
4982615 Sultan et al. Jan 1991 A
5087617 Smith Feb 1992 A
5126239 Livak et al. Jun 1992 A
5137806 LeMaistre et al. Aug 1992 A
5149506 Skiba et al. Sep 1992 A
5196167 Guadagno et al. Mar 1993 A
5200314 Urdea Apr 1993 A
5248671 Smith Sep 1993 A
5272057 Smulson et al. Dec 1993 A
5302509 Cheeseman Apr 1994 A
5330892 Vogelstein et al. Jul 1994 A
5331973 Fiedler et al. Jul 1994 A
5348855 Dattagupta et al. Sep 1994 A
5352775 Albertsen et al. Oct 1994 A
5362623 Vogelstein et al. Nov 1994 A
5369004 Polymeropoulos et al. Nov 1994 A
5378602 Polymeropoulos et al. Jan 1995 A
5380645 Vogelstein Jan 1995 A
5380647 Bahar Jan 1995 A
5382510 Levine et al. Jan 1995 A
5409586 Kamahori et al. Apr 1995 A
5416025 Krepinsky et al. May 1995 A
5458761 Kamahori et al. Oct 1995 A
5463782 Carlson et al. Nov 1995 A
5466576 Schulz et al. Nov 1995 A
5468610 Polymeropoulos et al. Nov 1995 A
5468613 Erlich et al. Nov 1995 A
5482834 Gillespie Jan 1996 A
5489508 West et al. Feb 1996 A
5492808 de la Chapelle et al. Feb 1996 A
5496470 Lenhart Mar 1996 A
5506105 Haydock Apr 1996 A
5508164 Kausch et al. Apr 1996 A
5512441 Ronai Apr 1996 A
5514547 Balazs et al. May 1996 A
5527676 Vogelstein et al. Jun 1996 A
5532108 Vogelstein Jul 1996 A
5538851 Fach et al. Jul 1996 A
5559014 Estes et al. Sep 1996 A
5580729 Vogelstein Dec 1996 A
5589335 Kearney et al. Dec 1996 A
5599662 Respess Feb 1997 A
5612473 Wu et al. Mar 1997 A
5635352 Urdea et al. Jun 1997 A
5641628 Bianchi Jun 1997 A
5645995 Kieback Jul 1997 A
5670325 Lapidus et al. Sep 1997 A
5688643 Oka et al. Nov 1997 A
5709998 Kinzler et al. Jan 1998 A
5710028 Eyal et al. Jan 1998 A
5741650 Lapidus et al. Apr 1998 A
5759777 Kearney et al. Jun 1998 A
5830665 Shuber et al. Nov 1998 A
5846710 Bajaj Dec 1998 A
5856104 Chee et al. Jan 1999 A
5882865 Vogelstein et al. Mar 1999 A
5888778 Shuber Mar 1999 A
5910407 Vogelstein et al. Jun 1999 A
5916744 Taylor Jun 1999 A
5928870 Lapidus et al. Jul 1999 A
5942396 Shiff et al. Aug 1999 A
5952178 Lapidus et al. Sep 1999 A
5976800 Lau et al. Nov 1999 A
6020137 Lapidus et al. Feb 2000 A
6037465 Hillebrand et al. Mar 2000 A
6084091 Muller et al. Jul 2000 A
6100029 Lapidus et al. Aug 2000 A
6143529 Lapidus et al. Nov 2000 A
6146828 Lapidus Nov 2000 A
6150100 Ruschoff et al. Nov 2000 A
6177251 Vogelstein et al. Jan 2001 B1
6203993 Shuber et al. Mar 2001 B1
6214187 Hammond et al. Apr 2001 B1
6214558 Shuber et al. Apr 2001 B1
6228596 Macina et al. May 2001 B1
6238927 Abrams et al. May 2001 B1
6251660 Muir et al. Jun 2001 B1
6268136 Shuber et al. Jul 2001 B1
6280947 Shuber et al. Aug 2001 B1
6300077 Shuber et al. Oct 2001 B1
6303304 Shuber et al. Oct 2001 B1
6351857 Slaon, III et al. Mar 2002 B2
6406857 Shuber et al. Jun 2002 B1
6415455 Slaon, III et al. Jul 2002 B1
6428964 Shuber Aug 2002 B1
6448002 Hillebrand et al. Sep 2002 B1
6475738 Shuber et al. Nov 2002 B2
6482595 Shuber et al. Nov 2002 B2
6498012 Laken Dec 2002 B2
6503718 Shuber et al. Jan 2003 B2
6551777 Shuber et al. Apr 2003 B1
6586177 Shuber Jul 2003 B1
20010018180 Shuber et al. Aug 2001 A1
20010039012 Lapidus Nov 2001 A1
20010042264 Sloan et al. Nov 2001 A1
20020001800 Lapidus Jan 2002 A1
20020004201 Lapidus et al. Jan 2002 A1
20020025525 Shuber Feb 2002 A1
20020040498 Sloan et al. Apr 2002 A1
20020045183 Shuber et al. Apr 2002 A1
20020048752 Lapidus et al. Apr 2002 A1
20020064787 Shuber et al. May 2002 A1
20020110810 Shuber Aug 2002 A1
20020119469 Shuber et al. Aug 2002 A1
20020119472 Lapidus et al. Aug 2002 A1
20020123052 Laken Sep 2002 A1
20020132251 Shuber Sep 2002 A1
20020164631 Shuber et al. Nov 2002 A1
20030044780 Lapidus et al. Mar 2003 A1
20030049659 Lapidus et al. Mar 2003 A1
20030087258 Shuber May 2003 A1
Foreign Referenced Citations (116)
Number Date Country
A-1132595 Oct 1994 AU
711754 Jul 1997 AU
704696 Aug 1997 AU
745862 Sep 1998 AU
744746 Jan 1999 AU
720489 Sep 1999 AU
AU199942333 Sep 1999 AU
2228769 Feb 1997 CA
2211702 May 1999 CA
195 30 132 Feb 1997 DE
195 30 132 Feb 1997 DE
197 12 332 Oct 1998 DE
197 36 691 Feb 1999 DE
0 270 017 Jun 1988 EP
0 270 017 Jun 1988 EP
0 284 362 Sep 1988 EP
0 284 362 Sep 1988 EP
0 337 498 Oct 1989 EP
0 390 323 Oct 1990 EP
0 390 323 Oct 1990 EP
0 391 565 Oct 1990 EP
0 407 789 Jan 1991 EP
0 407 789 Jan 1991 EP
0 608 004 Jul 1994 EP
0 259 031 Nov 1994 EP
0 648 845 Apr 1995 EP
0 664 339 Jul 1995 EP
2327497 Jan 1999 GB
3325270 Sep 2002 JP
WO 9009455 Aug 1990 WO
WO 9213103 Aug 1992 WO
WO 9216657 Oct 1992 WO
WO 9318186 Sep 1993 WO
WO 9320233 Oct 1993 WO
WO 9320235 Oct 1993 WO
WO 9400603 Jan 1994 WO
WO 9401447 Jan 1994 WO
WO 9409161 Apr 1994 WO
WO 9410575 May 1994 WO
WO 9411383 May 1994 WO
WO 9500669 Jan 1995 WO
WO 9507361 Mar 1995 WO
WO 9509928 Apr 1995 WO
WO 9509929 Apr 1995 WO
WO 9512606 May 1995 WO
WO 9513397 May 1995 WO
WO 9515400 Jun 1995 WO
WO 9516792 Jun 1995 WO
WO 9518818 Jul 1995 WO
WO 9519448 Jul 1995 WO
WO 9525813 Sep 1995 WO
WO 9531728 Nov 1995 WO
WO 9601907 Jan 1996 WO
WO 9606951 Mar 1996 WO
WO 9608514 Mar 1996 WO
WO 9612821 May 1996 WO
WO 9613611 May 1996 WO
WO 9623895 Aug 1996 WO
WO 9629430 Sep 1996 WO
WO 9630545 Oct 1996 WO
WO 9707239 Feb 1997 WO
WO 9709449 Mar 1997 WO
WO 9709600 Mar 1997 WO
WO 9719191 May 1997 WO
WO 9723651 Jul 1997 WO
WO 9725442 Jul 1997 WO
WO 9728450 Aug 1997 WO
WO 9808971 Mar 1998 WO
WO 9838338 Sep 1998 WO
WO 9839478 Sep 1998 WO
WO 9858081 Dec 1998 WO
WO 9858084 Dec 1998 WO
WO 9907894 Feb 1999 WO
WO 9907895 Feb 1999 WO
WO 9910528 Mar 1999 WO
WO 9920798 Apr 1999 WO
WO 9926724 Jun 1999 WO
WO 9928507 Jun 1999 WO
WO 9945147 Sep 1999 WO
WO 9945374 Sep 1999 WO
WO 9953316 Oct 1999 WO
WO 9955912 Nov 1999 WO
WO 9960160 Nov 1999 WO
WO 9960161 Nov 1999 WO
WO 9960162 Nov 1999 WO
WO 9966077 Dec 1999 WO
WO 9966078 Dec 1999 WO
WO 9966079 Dec 1999 WO
WO 0009751 Feb 2000 WO
WO 0011215 Mar 2000 WO
WO 0031298 Jun 2000 WO
WO 0031305 Jun 2000 WO
WO 0031313 Jun 2000 WO
WO 0032820 Jun 2000 WO
WO 0050640 Aug 2000 WO
WO 0050870 Aug 2000 WO
WO 0058514 Oct 2000 WO
WO 0060118 Oct 2000 WO
WO 0061808 Oct 2000 WO
WO 0066005 Nov 2000 WO
WO 0070096 Nov 2000 WO
WO 0070096 Nov 2000 WO
WO0111083 Feb 2001 WO
WO0111083 Feb 2001 WO
WO 0118252 Mar 2001 WO
WO 0142502 Jun 2001 WO
WO 0142503 Jun 2001 WO
WO 0142781 Jun 2001 WO
WO0164950 Sep 2001 WO
WO0164950 Sep 2001 WO
WO02055740 Jul 2002 WO
WO02059379 Aug 2002 WO
WO02074995 Sep 2002 WO
WO02092858 Nov 2002 WO
WO 03044217 May 2003 WO
WO 03071252 Aug 2003 WO
Provisional Applications (1)
Number Date Country
60128629 Apr 1999 US